Advertisement

Topics

CX-01 Heparin Derivative Investigated for Older Patients With AML

20:00 EDT 13 Jun 2019 | Cancer Networks

A randomized phase II trial investigated whether adding CX-01, a low anticoagulant heparin derivative, to standard care improves outcomes in older patients with acute myeloid leukemia.

Original Article: CX-01 Heparin Derivative Investigated for Older Patients With AML

NEXT ARTICLE

More From BioPortfolio on "CX-01 Heparin Derivative Investigated for Older Patients With AML"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...